fluoxetine has been researched along with Chronic Motor and Vocal Tic Disorder in 25 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To develop a mouse model to mimic the behavioral and neurochemical changes of Tourette syndrome (TS) by 1-(2, 5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) induction and to investigate the effects of fluoxetine and haloperidol on head twitch response (HTR) induced by DOI." | 3.74 | [Roles of fluoxetine and haloperidol in mouse models of DOI-induced head twitch response]. ( Dai, XM; Lu, Y; Ma, HW; Yao, Y, 2007) |
| "The frequent comorbidity of OCD and Sydenham's chorea and similar postulates of basal ganglia dysfunction for both disorders suggest that Sydenham's chorea may serve as a medical model for OCD." | 2.39 | Childhood movement disorders and obsessive compulsive disorder. ( Leonard, HL; Swedo, SE, 1994) |
| "Tourette syndrome is defined and characterized mainly by the presence of motor and phonic tics." | 1.32 | Effects of medications on regulation of body temperature of patients with Tourette syndrome. ( Kessler, AR, 2004) |
| " In general, fluoxetine, which was administered from 4 to 20 weeks at a dosage of 10 or 40 mg per day, was well tolerated." | 1.28 | Fluoxetine treatment of children and adolescents with Tourette's and obsessive compulsive disorders: preliminary clinical experience. ( Hardin, MT; King, R; Riddle, MA; Scahill, L; Woolston, JL, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (8.00) | 18.7374 |
| 1990's | 16 (64.00) | 18.2507 |
| 2000's | 4 (16.00) | 29.6817 |
| 2010's | 2 (8.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, D | 1 |
| Tian, HL | 1 |
| Cui, X | 1 |
| Wang, Q | 1 |
| Guo, F | 1 |
| Zhang, W | 1 |
| Tang, QS | 1 |
| Rizzo, R | 1 |
| Gulisano, M | 1 |
| Calì, PV | 1 |
| Di Pino, A | 1 |
| Rickards, H | 1 |
| Cavanna, AE | 1 |
| Worrall, R | 1 |
| Kessler, AR | 1 |
| Kotcher, L | 1 |
| Wieland, N | 1 |
| Coffey, B | 1 |
| Yao, Y | 1 |
| Ma, HW | 1 |
| Lu, Y | 1 |
| Dai, XM | 1 |
| Knott, PJ | 1 |
| Hutson, PH | 1 |
| Giakas, WJ | 1 |
| Barak, Y | 1 |
| Szor, H | 1 |
| Ring, A | 1 |
| Sarova-Pinhas, I | 1 |
| Lampl, Y | 1 |
| Swedo, SE | 1 |
| Leonard, HL | 1 |
| Gatto, E | 1 |
| Pikielny, R | 1 |
| Micheli, F | 1 |
| Dimitsopulos, T | 1 |
| Kurlan, R | 3 |
| Como, PG | 2 |
| Deeley, C | 1 |
| McDermott, M | 1 |
| McDermott, MP | 1 |
| Eapen, V | 1 |
| Trimble, MR | 2 |
| Robertson, MM | 1 |
| Scahill, L | 2 |
| Riddle, MA | 3 |
| King, RA | 1 |
| Hardin, MT | 3 |
| Rasmusson, A | 1 |
| Makuch, RW | 1 |
| Leckman, JF | 2 |
| Peterson, BS | 1 |
| Cohen, DJ | 2 |
| Emslie, GJ | 1 |
| Weinberg, WA | 1 |
| Mayes, TL | 1 |
| Granana, N | 1 |
| Tuchman, RF | 1 |
| Sallee, FR | 1 |
| DeVane, CL | 1 |
| Ferrell, RE | 1 |
| George, MS | 1 |
| Goodman, WK | 1 |
| McDougle, CJ | 1 |
| Price, LH | 1 |
| Kerbeshian, J | 1 |
| Burd, L | 1 |
| King, R | 1 |
| Woolston, JL | 1 |
| Anderson, GM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Transcranial Magnetic Stimulation for Individuals With Tourette's Syndrome[NCT00529308] | Phase 2 | 20 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
| Intervention | participants (Number) |
|---|---|
| Active | 2 |
| Sham | 8 |
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
| Intervention | participants (Number) |
|---|---|
| Active | 1 |
| Sham | 0 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
| Intervention | µV (Mean) |
|---|---|
| Active | 56.5 |
| Sham | 63.8 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
| Intervention | µV (Mean) |
|---|---|
| Active | 56 |
| Sham | 59.8 |
Y-GTSS is a clinician-rated scale used to assess tic severity. Motor and phonic tics are rated separately from 0 to 5 on several scales including number, frequency, intensity, complexity, and interference. Thus Motor and Phonic Tic scores can range from 0 to 25; the combined Total Tic Score ranges from 0 to 50. There is also an Impairment score that rates the overall burden due to tics. The Impairment scale yields a single score from 0 to 50 with higher scores indicating higher levels of overall impairment associated with tics. (NCT00529308)
Timeframe: 3 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active | 29.5 |
| Sham | 31.5 |
3 reviews available for fluoxetine and Chronic Motor and Vocal Tic Disorder
| Article | Year |
|---|---|
Childhood movement disorders and obsessive compulsive disorder.
Topics: Antipsychotic Agents; Child; Chorea; Clinical Trials as Topic; Clomipramine; Comorbidity; Female; Fl | 1994 |
The treatment of Tourette's syndrome: multimodal, developmental intervention.
Topics: Adaptation, Psychological; Adolescent; Adrenergic Agonists; Adult; Age Factors; Antidepressive Agent | 1998 |
The role of serotonin and dopamine in the pathophysiology of obsessive compulsive disorder.
Topics: Brain; Clomipramine; Dopamine; Fluoxetine; Fluvoxamine; Humans; Obsessive-Compulsive Disorder; Serot | 1992 |
6 trials available for fluoxetine and Chronic Motor and Vocal Tic Disorder
| Article | Year |
|---|---|
A pilot controlled study of fluoxetine for obsessive-compulsive symptoms in children with Tourette's syndrome.
Topics: Adolescent; Child; Double-Blind Method; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Pil | 1993 |
The use of fluoxetine in Gilles de la Tourette syndrome and obsessive compulsive behaviours: preliminary clinical experience.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Child, Preschool; Family Practice; Fema | 1996 |
Fluoxetine has no marked effect on tic symptoms in patients with Tourette's syndrome: a double-blind placebo-controlled study.
Topics: Adolescent; Adult; Akathisia, Drug-Induced; Child; Cross-Over Studies; Double-Blind Method; Female; | 1997 |
Treatment of children with antidepressants: focus on selective serotonin reuptake inhibitors.
Topics: Adolescent; Anxiety Disorders; Child; Depressive Disorder; Double-Blind Method; Fluoxetine; Humans; | 1998 |
An open-label trial of fluoxetine for obsessive-compulsive disorder in Gilles de la Tourette's syndrome.
Topics: Adolescent; Child; Female; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Psychiatric Stat | 1991 |
Fluoxetine treatment of obsessions and compulsions in patients with Tourette's syndrome.
Topics: Adult; Clinical Trials as Topic; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Propylamin | 1988 |
16 other studies available for fluoxetine and Chronic Motor and Vocal Tic Disorder
| Article | Year |
|---|---|
Effects of Jian-Pi-Zhi-Dong Decoction on the Expression of 5-HT and Its Receptor in a Rat Model of Tourette Syndrome and Comorbid Anxiety.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Behavior, Animal; Cerebral Cortex; Corpu | 2020 |
Mandatory electrocardiographic monitoring in young patients treated with psychoactive drugs.
Topics: Antipsychotic Agents; Child; Electrocardiography; Fluoxetine; Humans; Long QT Syndrome; Male; Pimozi | 2013 |
Treatment practices in Tourette syndrome: the European perspective.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety; Aripiprazole; Atomoxetine Hydrochloride | 2012 |
Effects of medications on regulation of body temperature of patients with Tourette syndrome.
Topics: Adolescent; Adult; Body Temperature Regulation; Child; Child, Preschool; Circadian Rhythm; Clonidine | 2004 |
Trichotillomania and co-morbid psychiatric disorders in a 10-year-old boy.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Clonidine; Comorbidity; Drug Therapy, Combinat | 2007 |
[Roles of fluoxetine and haloperidol in mouse models of DOI-induced head twitch response].
Topics: Amphetamines; Animals; Disease Models, Animal; Dopamine; Fluoxetine; Haloperidol; Homovanillic Acid; | 2007 |
Stress-induced stereotypy in the rat: neuropharmacological similarities to Tourette syndrome.
Topics: Animals; Disease Models, Animal; Fenfluramine; Fluoxetine; Humans; Male; Nervous System; p-Chloroamp | 1982 |
Risperidone treatment for a Tourette's disorder patient with comorbid obsessive-compulsive disorder.
Topics: Adult; Antipsychotic Agents; Comorbidity; Depressive Disorder; Drug Therapy, Combination; Fluoxetine | 1995 |
Tourette's disorder.
Topics: Diagnosis, Differential; Female; Fluoxetine; Humans; Israel; Jews; Middle Aged; Prognosis; Tourette | 1994 |
Fluoxetine in Tourette's syndrome.
Topics: Acute Disease; Adult; Fluoxetine; Humans; Male; Nail Biting; Obsessive-Compulsive Disorder; Severity | 1994 |
Tourette's syndrome and nicotine withdrawal.
Topics: Adult; Female; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Smoking Cessation; Tourette Syndro | 1993 |
A child with severe head banging.
Topics: Autistic Disorder; Child; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Selective Seroton | 1999 |
Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency.
Topics: Antipruritics; Attention Deficit Disorder with Hyperactivity; Child; Cytochrome P-450 CYP2D6; Dopami | 2000 |
A fluvoxamine-induced frontal lobe syndrome in a patient with comorbid Gilles de la Tourette's syndrome and obsessive compulsive disorder.
Topics: Adult; Brain Diseases; Dopamine; Fluoxetine; Frontal Lobe; Humans; Male; Obsessive-Compulsive Disord | 1992 |
Tourette syndrome and recurrent paraphilic masturbatory fantasy.
Topics: Adult; Fantasy; Fluoxetine; Humans; Male; Masturbation; Paraphilic Disorders; Recurrence; Tourette S | 1991 |
Fluoxetine treatment of children and adolescents with Tourette's and obsessive compulsive disorders: preliminary clinical experience.
Topics: Adolescent; Akathisia, Drug-Induced; Child; Female; Fluoxetine; Humans; Male; Obsessive-Compulsive D | 1990 |